Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 5:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Stage 0 Laryngeal Cancer Clear all

Recruiting Not applicable Interventional

Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

NCT01473784

View directory record Official record

Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage 0 Hypopharyngeal Cancer, Stage 0 Laryngeal Cancer, Stage 0 Lip and Oral Cavity Cancer, Stage I Adenoid Cystic Carcinoma of the Oral Cavity, Stage I Mucoepidermoid Carcinoma of the Oral Cavity, Stage I Squamous Cell Carcinoma of the Hypopharynx, Stage I Squamous Cell Carcinoma of the Larynx, Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage I Verrucous Carcinoma of the Larynx, Stage I Verrucous Carcinoma of the Oral Cavity, Stage II Adenoid Cystic Carcinoma of the Oral Cavity, Stage II Mucoepidermoid Carcinoma of the Oral Cavity, Stage II Squamous Cell Carcinoma of the Hypopharynx, Stage II Squamous Cell Carcinoma of the Larynx, Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage II Verrucous Carcinoma of the Larynx, Stage II Verrucous Carcinoma of the Oral Cavity, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Mucoepidermoid Carcinoma of the Oral Cavity, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
Interventions: transoral robotic surgery, quality of life assessment; Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older

Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Source: ClinicalTrials.gov public record

Updated Feb 9, 2026 · Synced May 21, 2026, 5:34 PM EDT

Completed Phase 1Phase 2 Interventional

Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.

NCT01469429

View directory record Official record

Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage 0 Hypopharyngeal Cancer, Stage 0 Laryngeal Cancer, Stage 0 Lip and Oral Cavity Cancer, Stage 0 Nasopharyngeal Cancer, Stage 0 Oropharyngeal Cancer, Stage 0 Paranasal Sinus and Nasal Cavity Cancer, Stage I Salivary Gland Cancer, Stage I Squamous Cell Carcinoma of the Hypopharynx, Stage I Squamous Cell Carcinoma of the Larynx, Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage I Squamous Cell Carcinoma of the Nasopharynx, Stage I Squamous Cell Carcinoma of the Oropharynx, Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage I Verrucous Carcinoma of the Larynx, Stage I Verrucous Carcinoma of the Oral Cavity, Stage II Salivary Gland Cancer, Stage II Squamous Cell Carcinoma of the Hypopharynx, Stage II Squamous Cell Carcinoma of the Larynx, Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage II Squamous Cell Carcinoma of the Nasopharynx, Stage II Squamous Cell Carcinoma of the Oropharynx, Stage II Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage II Verrucous Carcinoma of the Larynx, Stage II Verrucous Carcinoma of the Oral Cavity, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Oral Cavity Squamous Cell Carcinoma, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Nasal Cavity and Paranasal Sinus Cancer, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Oral Cavity Squamous Cell Carcinoma, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Oral Cavity Squamous Cell Carcinoma, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Paranasal Sinus and Nasal Cavity Squamous Cell Carcinoma, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
Interventions: placebo, laboratory biomarker analysis, questionnaire administration, chemoprevention; Other · Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 21 Years and older

Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Source: ClinicalTrials.gov public record

Updated Feb 19, 2020 · Synced May 21, 2026, 5:34 PM EDT

Completed Phase 3 Interventional

Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer

NCT00008398

View directory record Official record

Conditions: Head and Neck Cancer, Oral Complications, Radiation Toxicity
Interventions: sargramostim, quality-of-life assessment, radiation therapy; Biological · Procedure · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: Not listed

Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 217
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 167 more

Source: ClinicalTrials.gov public record

Updated Nov 18, 2013 · Synced May 21, 2026, 5:34 PM EDT

Terminated Not applicable Interventional Results available

Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Recurrent Mouth or Throat Dysplasia or Recurrent In Situ Cancer or Stage I Cancer of the Mouth or Throat

NCT00530088

View directory record Official record

Conditions: Head and Neck Cancer
Interventions: porfimer sodium, Photdynamic Therapy (PDT); Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older

Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 1
States / cities: Buffalo, New York

Source: ClinicalTrials.gov public record

Updated Jul 3, 2014 · Synced May 21, 2026, 5:34 PM EDT

Completed Phase 2 Interventional

Porfimer Sodium in Diagnosing Patients With Head and Neck Cancer

NCT00002964

View directory record Official record

Conditions: Head and Neck Cancer
Interventions: porfimer sodium, fluorophotometry; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older

Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 1
States / cities: Buffalo, New York

Source: ClinicalTrials.gov public record

Updated Feb 4, 2013 · Synced May 21, 2026, 5:34 PM EDT

Completed Phase 1 Interventional

Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors

NCT00978081

View directory record Official record

Conditions: Head and Neck Cancer, Precancerous Condition
Interventions: aminolevulinic acid hydrochloride; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years to 120 Years

Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Source: ClinicalTrials.gov public record

Updated Apr 22, 2019 · Synced May 21, 2026, 5:34 PM EDT

Completed Phase 1 Interventional

Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx

NCT00675233

View directory record Official record

Conditions: Head and Neck Cancer
Interventions: HPPH, laser therapy; Drug · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older

Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: Buffalo, New York

Source: ClinicalTrials.gov public record

Updated Oct 16, 2018 · Synced May 21, 2026, 5:34 PM EDT

Recruiting Phase 2 Interventional

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

NCT06532279

View directory record Official record

Conditions: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Stage 0 Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage 0 Hypopharyngeal Carcinoma AJCC v8, Stage 0 Nasopharyngeal Carcinoma AJCC v8, Stage 0 Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage I Hypopharyngeal Carcinoma AJCC v8, Stage I Laryngeal Cancer AJCC v8, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage I Nasopharyngeal Carcinoma AJCC v8, Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage II Hypopharyngeal Carcinoma AJCC v8, Stage II Laryngeal Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage II Nasopharyngeal Carcinoma AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stomatitis
Interventions: Best Practice, Biospecimen Collection, Cisplatin, Computed Tomography, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, MnSOD Mimetic BMX-001, Placebo Administration, Questionnaire Administration; Other · Procedure · Drug + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older

Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 149
States / cities: Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 122 more

Source: ClinicalTrials.gov public record

Updated May 3, 2026 · Synced May 21, 2026, 5:34 PM EDT

Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850

View directory record Official record

Conditions: Cancer
Interventions: Fentanyl sublingual spray, Placebo; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 18 Years and older

Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Chandler, Arizona

Source: ClinicalTrials.gov public record

Updated Mar 4, 2014 · Synced May 21, 2026, 5:34 PM EDT

Completed Early Phase 1 Interventional Accepts healthy volunteers

Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5

NCT00743353

View directory record Official record

Conditions: Sarcoma, Melanoma, Lung Cancer, Breast Cancer, High Grade Gliomas
Interventions: F-18 RGD-K5; Drug
Lead sponsor: Siemens Molecular Imaging; Industry
Eligibility: 18 Days and older

Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Source: ClinicalTrials.gov public record

Updated Feb 1, 2009 · Synced May 21, 2026, 5:34 PM EDT